Skip to search formSkip to main contentSkip to account menu

exenatide 2 MG Injection [Bydureon]

Known as: BYDUREON KIT, Bydureon 2 MG Injection, EXENATIDE 2 mg in 0.65 mL SUBCUTANEOUS INJECTION, POWDER, FOR SUSPENSION [Bydureon] 
National Institutes of Health

Related topics

Related topics

8 relations
BydureonCarboxymethylcellulose SodiumInjectionPolysorbate 20

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Quality by Design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery.
2017
2017
No cognitive‐enhancing effect of GLP‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia
Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon‐like peptide‐1 receptor agonists (GLP… 
Review
2017
Review
2017
A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
IntroductionExenatide once weekly (ExeOW, Bydureon®, Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP… 
Review
2015
Review
2015
Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus
Exenatide extended-release (exenatide ER) [Bydureon®] is a glucagon-like peptide-1 receptor agonist, approved for the treatment… 
2015
2015
P356 Effets du Bydureon® sur le contrôle glycémique et le poids: résultats préliminaires
2014
2014
Eosinophil‐rich granulomatous panniculitis caused by exenatide injection
To the Editor, Medications administered subcutaneously have become more common, and some drugs may cause cutaneous injection site… 
2014
2014
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness…
2013
2013
An Evidence-Based and Practical Approach to Using Bydureon™ in Patients With Type 2 Diabetes
Glucagon-like peptide (GLP)-1 agonists are one of the newer classes of medications for use in type 2 diabetes. There are… 
Review
2012
Review
2012
The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
In people with type 2 diabetes mellitus (T2DM), the incretin effect is reduced, but the recent advent of dipeptidyl peptidase‐4… 
Review
2012
Review
2012
Exenatide Extended-Release
Subcutaneous exenatide extended-release (ER; Bydureon™; also known as exenatide once weekly), a glucagon-like peptide-1 receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)